ArriVent BioPharma Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ArriVent BioPharma Inc
Access all reports
ArriVent BioPharma Inc. is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of innovative medicines to meet the unmet medical needs of patients with cancers. The company specializes in developing targeted cancer therapies, including for non-small-cell lung cancer (NSCLC) and other solid tumors. A key product in its pipeline is Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
AVBP
Country
🇺🇸 United States